ArticleNutrition journal2026
Association between high-risk metabolic dysfunction-associated steatohepatitis and ischemic heart disease: a nationally representative study.
Article in Nutrition journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe relationship between metabolic dysfunction-associated steatohepatitis (MASH) and ischemic heart disease (IHD) remains incompletely understood. This study investigated this association in the U.S. adults utilizing the FibroScan-AST (FAST) score, a validated non-invasive tool for identifying high-risk MASH.
methodsThis cross-sectional study included 3,696 adults in the 2017-2018 National Health and Nutrition Examination Survey. We defined high-risk MASH as FAST score ≥ 0.35. We performed logistic regression to investigate the association between high-risk MASH and prevalent IHD. FAST was calculated by liver stiffness measurement (LSM), controlled attenuation parameter (CAP), and aspartate aminotransferase (AST).
resultsThe prevalence of IHD was significantly higher in the high-risk MASH group than in the non-high-risk group (10.5% vs. 5.8%). Both LSM (adjusted odds ratio (aOR) 1.84, 95% CI 1.28-2.65) and CAP (aOR 3.06, 95% CI 1.32-7.12) were independently associated with IHD after adjustment, whereas AST did not demonstrate a significant association (aOR 0.83, 95% CI 0.48-1.43). High-risk MASH was independently associated with IHD (aOR: 2.08; 95% CI: 1.18-3.65). Subgroup analysis suggested a potential sex-specific interaction (P for interaction = 0.035), with a pronounced association in males (aOR: 2.51; 95% CI: 1.32-4.75) but was not statistically significant in females (aOR: 0.36, 95% CI 0.07-1.27).
conclusionHigh-risk MASH defined by the FAST score is independently associated with prevalent IHD in the U.S. POPULATION: Future prospective cohort studies are warranted to validate whether intervation of high-risk MASH improves cardiovascular outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.